Industrial and academic approaches to the search for alternative melatonin receptor ligands: An historical survey.
agonists
chemical approach
ligands
melatonin
receptor
Journal
Journal of pineal research
ISSN: 1600-079X
Titre abrégé: J Pineal Res
Pays: England
ID NLM: 8504412
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
revised:
05
03
2024
received:
07
10
2023
accepted:
24
03
2024
medline:
29
4
2024
pubmed:
29
4
2024
entrez:
29
4
2024
Statut:
ppublish
Résumé
The search for melatonin receptor agonists formed the main part of melatonin medicinal chemistry programs for the last three decades. In this short review, we summarize the two main aspects of these programs: the development of all the necessary tools to characterize the newly synthesized ligands at the two melatonin receptors MT
Substances chimiques
Ligands
0
Receptor, Melatonin, MT2
0
Receptor, Melatonin, MT1
0
Receptors, Melatonin
0
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12953Subventions
Organisme : European Union - NextGenerationEU
Organisme : VITALITY - CUP H33C22000430006
Organisme : National Innovation Ecosystem grant ECS00000041
Organisme : Deutscher Akademischer Austauschdienst
Organisme : Bundesministerium für Bildung und Forschung
Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Axelrod J, Wurtman RJ. The formation, metabolism and some actions of melatonin, a pineal gland substance. Res Publ Assoc Res Nerv Ment Dis. 1966;43:200‐211.
Huether G. The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experientia. 1993;49:665‐670.
Arendt J, Aulinas A, 2000. Endotext: Physiology of the pineal gland and melatonin.
Cassone VM, Warren WS, Brooks DS, et al. Melatonin, the pineal gland, and circadian rhythms. J Biol Rhythms. 1993;8(suppl):S73‐S81.
Malpaux B, Viguié C, Skinner DC, Thiéry JC, Chemineau P. Control of the circannual rhythm of reproduction by melatonin in the ewe. Brain Res Bull. 1997;44:431‐438.
Boutin JA, Ferry G. Is there sufficient evidence that the melatonin binding site MT3 is quinone reductase 2? J Pharmacol Exp Ther. 2019;368:59‐65.
Liu L, Labani N, Cecon E, Jockers R. Melatonin target proteins: too many or not enough? Front Endocrinol. 2019;10:791.
Gautier C, Theret I, Lizzo G, et al. Why are we still cloning melatonin receptors? A commentary. Methods Mol Biol. 2022;2550:267‐281.
Yin X, Bai Y‐L, Gong C, et al. The phytomelatonin receptor PMTR1 regulates seed development and germination by modulating abscisic acid homeostasis in Arabidopsis thaliana. J Pineal Res. 2022;72:e12797.
Zhang Y, Dai M, Wu Z, et al. Melatonin receptor, GhCAND2‐D5 motivated responding to NaCl signaling in cotton. Plant Physiol Biochem. 2023;203:108001.
Jockers R, Delagrange P, Dubocovich ML, et al. Update on melatonin receptors: IUPHAR review 20. Br J Pharmacol. 2016;173:2702‐2725.
Cecon E, Boutin JA, Jockers R. Molecular characterization and pharmacology of melatonin receptors in animals. Receptors. 2023;2:127‐147.
Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron. 1994;13:1177‐1185.
Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Nat Acad Sci. 1995;92:8734‐8738.
Ebisawa T, Karne S, Lerner MR, Reppert SM. Expression cloning of a high‐affinity melatonin receptor from Xenopus dermal melanophores. Proc Nat Acad Sci. 1994;91:6133‐6137.
Vanecek J. Cellular mechanisms of melatonin action. Physiol Rev. 1998;78:687‐721.
Johansson LC, Stauch B, McCorvy JD, et al. XFEL structures of the human MT2 melatonin receptor reveal the basis of subtype selectivity. Nature. 2019;569:289‐292.
Stauch B, Johansson LC, McCorvy JD, et al. Structural basis of ligand recognition at the human MT1 melatonin receptor. Nature. 2019;569:284‐288.
Forman HJ, Davies KJA, Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para‐hormesis versus free radical scavenging in vivo. Free Radic Biol Med. 2014;66:24‐35.
Forman HJ, Augusto O, Brigelius‐Flohe R, et al. Even free radicals should follow some rules: a guide to free radical research terminology and methodology. Free Radic Biol Med. 2015;78:233‐235.
Forman HJ, Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discovery. 2021;20:689‐709.
Boutin JA, Jockers R. Melatonin controversies, an update. J Pineal Res. 2021;70:e12702.
Boutin JA, Kennaway DJ, Jockers R. Melatonin: facts, extrapolations and clinical trials. Biomolecules. 2023;13:943.
Dubbels R, Reiter RJ, Klenke E, et al. Melatonin in edible plants identified by radioimmunoassay and by high performance liquid chromatography‐mass spectrometry. J Pineal Res. 1995;18:28‐31.
Hattori A, Migitaka H, Iigo M, et al. Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem Mol Biol Int. 1995;35:627‐634.
Murch SJ, Erland LAE. A systematic review of melatonin in plants: an example of evolution of literature. Front Plant Sci. 2021;12:683047.
Hickie IB, Rogers NL. Novel melatonin‐based therapies: potential advances in the treatment of major depression. The Lancet. 2011;378:621‐631.
Kasper S, Corruble E, Hale A, Lemoine P, Montgomery SA, Quera‐Salva MA. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head‐to‐head studies without a placebo control. Int Clin Psychopharmacol. 2013;28:12‐19.
Millan MJ. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action. Ther Adv Psychopharmacol. 2022;12:204512532211051.
Legros C, Dupré C, Brasseur C, et al. Characterization of the various functional pathways elicited by synthetic agonists or antagonists at the melatonin MT1 and MT2 receptors. Pharmacol Res Perspect. 2020;8:e00539.
Ma S, Li C, Yan C, et al. Melatonin alleviates early brain injury by inhibiting the NRF2‐mediated ferroptosis pathway after subarachnoid hemorrhage. Free Radic Biol Med. 2023;208:555‐570.
Durkina AV, Szeiffova Bacova B, Bernikova OG, et al. Blockade of melatonin receptors abolishes its antiarrhythmic effect and slows ventricular conduction in rat hearts. Int J Mol Sci. 2023;24:11931.
Boutin JA, Audinot V, Ferry G, Delagrange P. Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci. 2005;26:412‐419.
Boutin JA, Nosjean O, Ferry G. On the organization of a drug discovery platform. In: Bobbarala V, ed. Drug discovery ‐ Concepts to market. InTech; 2018.
Vakkuri O, Lämsä E, Rahkamaa E, Ruotsalainen H, Leppäluoto J. Iodinated melatonin: preparation and characterization of the molecular structure by mass and 1H NMR spectroscopy. Anal Biochem. 1984;142:284‐289.
Legros C, Matthey U, Grelak T, et al. New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. Int J Mol Sci. 2013;14:8948‐8962.
Legros C, Brasseur C, Delagrange P, Ducrot P, Nosjean O, Boutin JA. Alternative radioligands for investigating the molecular pharmacology of melatonin receptors. J Pharmacol Exp Ther. 2016;356:681‐692.
Legros C, Devavry S, Caignard S, et al. Melatonin MT1 and MT2 receptors display different molecular pharmacologies only in the G‐protein coupled state. Br J Pharmacol. 2014;171:186‐201.
Audinot V, Bonnaud A, Grandcolas L, et al. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. Biochem Pharmacol. 2008;75:2007‐2019.
Gautier C, Dufour E, Dupré C, et al. Hamster melatonin receptors: cloning and binding characterization of MT₁ and attempt to clone MT₂. Int J Mol Sci. 2018;19(7):1957.
Devavry S, Legros C, Brasseur C, et al. Molecular pharmacology of the mouse melatonin receptors MT1 and MT2. Eur J Pharmacol. 2012;677:15‐21.
Cogé F, Guenin S, Fery I, et al. The end of a myth: cloning and characterization of the ovine melatonin MT(2) receptor. Br J Pharmacol. 2009;158:1248‐1262.
Mailliet F, Audinot V, Malpaux B, et al. Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors. Biochem Pharmacol. 2004;67:667‐677.
Guesdon V, Malpaux B, Delagrange P, et al. Rapid effects of melatonin on hormonal and behavioral stressful responses in ewes. Psychoneuroendocrinology. 2013;38:1426‐1434.
Cabaniols J‐P, Ouvry C, Lamamy V, et al. Meganuclease‐driven targeted integration in CHO‐K1 cells for the fast generation of HTS‐compatible cell‐based assays. SLAS Discovery. 2010;15:956‐967.
Vaidehi N, Grisshammer R, Tate CG. How can mutations thermostabilize G‐protein‐coupled receptors? Trends Pharmacol Sci. 2016;37:37‐46.
Logez C, Berger S, Legros C, et al. Recombinant human melatonin receptor MT1 isolated in mixed detergents shows pharmacology similar to that in mammalian cell membranes. PLoS One. 2014;9:e100616.
Logez C, Damian M, Legros C, et al. Detergent‐free isolation of functional G protein‐coupled receptors into nanometric lipid particles. Biochemistry. 2016;55:38‐48.
Stein RM, Kang HJ, McCorvy JD, et al. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. Nature. 2020;579:609‐614.
Yan J, Su H, Boutin JA, Renard MP, Wang M. High‐throughput screening assay for new ligands at human melatonin receptors. Acta Pharmacol Sin. 2008;29:1515‐1521.
Boutin JA, Lahaye C, Pegurier C, et al. Screening of ligand binding on melatonin receptor using non‐peptide combinatorial libraries. J Receptors Signal Transduction. 2000;20:105‐118.
Boutin JA, Witt‐Enderby PA, Sotriffer C, Zlotos DP. Melatonin receptor ligands: a pharmaco‐chemical perspective. J Pineal Res. 2020;69:e12672.
Okamoto HH, Cecon E, Nureki O, Rivara S, Jockers R. Melatonin receptor structure and signaling. J Pineal Res. 2024:e12952. In press.
Gerbier R, Jockers R. GTPγS binding assay for melatonin receptors in mouse brain tissue. Methods Mol Biol. 2022;2550:163‐169.
Dupré C, Bruno O, Bonnaud A, et al. Assessments of cellular melatonin receptor signaling pathways: β‐arrestin recruitment, receptor internalization, and impedance variations. Eur J Pharmacol. 2018;818:534‐544.
Dupré C, Legros C, Boutin JA. Functionality of melatonin receptors: recruitment of β‐arrestin at MT1. Methods Mol Biol. 2022;2550:195‐199.
Bonnaud A, Dupré C, Legros C, et al. MT1 receptor signaling pathways by impedance measurement. Methods Mol Biol. 2022;2550:201‐206.
Kenakin T. Emergent concepts of receptor pharmacology. Handb Exp Pharmacol. 2019;260:17‐41.
Kenakin T. Biased signaling as allosteric probe dependence. Cellular Signalling. 2021;79:109844.
Boutin JA, Leprince J. Biased agonism or “biaism” for the dummies, a commentary. Receptors. 2024;3:13‐26.
Boutin JA, Legros C. The five dimensions of receptor pharmacology exemplified by melatonin receptors: an opinion. Pharmacol Res Perspect. 2020;8:e00556.
Devavry S, Legros C, Brasseur C, et al. Description of the constitutive activity of cloned human melatonin receptors hMT(1) and hMT(2) and discovery of inverse agonists. J Pineal Res. 2012;53:29‐37.
Klosen P. 37 years of MT1 and MT2 melatonin receptor localization in the brain: past and future. J Pineal Res. 2024. In press.
Cecon E, Ivanova A, Luka M, et al. Detection of recombinant and endogenous mouse melatonin receptors by monoclonal antibodies targeting the C‐terminal domain. J Pineal Res. 2019;66:e12540.
Dubocovich ML. Pharmacology and function of melatonin receptors. FASEB J. 1988;2:2765‐2773.
Nosjean O, Ferro M, Cogé F, et al. Identification of the melatonin‐binding site MT3 as the quinone reductase 2. J Biol Chem. 2000;275:31311‐31317.
Mailliet F, Ferry G, Vella F, Thiam K, Delagrange P, Boutin JA. Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. FEBS Lett. 2004;578:116‐120.
Benoit C‐E, Bastianetto S, Brouillette J, et al. Loss of quinone reductase 2 function selectively facilitates learning behaviors. J Neurosci. 2010;30:12690‐12700.
Gould NL, Sharma V, Hleihil M, et al. Dopamine‐dependent QR2 pathway activation in CA1 interneurons enhances novel memory formation. J Neurosci. 2020;40:8698‐8714.
Vallucci M, Boutin JA, Janda E, et al. The specific NQO2 inhibitor, S29434, only marginally improves the survival of dopamine neurons in MPTP‐intoxicated mice. J Neural Transm. 2024;131:1‐11.
Gould NL, Scherer GR, Carvalho S, et al. Specific quinone reductase 2 inhibitors reduce metabolic burden and reverse Alzheimer's disease phenotype in mice. J Clin Invest. 2023;133(19):e162120.
Gautier C, Guenin S‐P, Riest‐Fery I, et al. Characterization of the Mel1c melatoninergic receptor in platypus (Ornithorhynchus anatinus). PLoS One. 2018;13:e0191904.
Huang L, Zhang C, Hou Y, et al. Blood pressure reducing effects of piromelatine and melatonin in spontaneously hypertensive rats. Eur Rev Med Pharmacol Sci. 2013;17:2449‐2456.
Zhou J, Wang D, Luo X, et al. Melatonin receptor agonist piromelatine ameliorates impaired glucose metabolism in chronically stressed rats fed a high‐fat diet. J Pharmacol Exp Ther. 2018;364:55‐69.
Schneider LS, Laudon M, Nir T, et al. A polymorphism cluster at the 2q12 locus may predict response to piromelatine in patients with mild Alzheimer's disease. J Prevent Alzheimer's Dis. 2022;9:247‐254.
Vakhitova YV, Kuzmina US, Voronin MV, Zainullina LF, Seredenin SB. Effect of fabomotizole on brain gene expression in MR rats in the open field test. Dokl Biochem Biophys. 2019;488:313‐315.
Syunyakov TS, Neznamov GG. [Evaluation of the therapeutic efficacy and safety of the selective anxiolytic afobazole in generalized anxiety disorder and adjustment disorders: results of a multicenter randomized comparative study of diazepam]. Ter Arkh. 2016;88:73‐86.
Gao N, Zheng W, Murezati T, Gu W, Li X, Jin Z. GW117: a novel serotonin (5‐HT2C) receptor antagonist and melatonin (MT1/MT2) receptor agonist with potential antidepressant‐like activity in rodents. CNS Neurosci Ther. 2021;27:702‐713.
Yang Y, Tiliwaerde M, Gao N, et al. Mechanism of GW117 antidepressant action: melatonin receptor‐mediated regulation of sleep rhythm. Eur J Pharmacol. 2024;964:176299.
Ferreira MA, Azevedo H, Mascarello A, et al. Discovery of ACH‐000143: a novel potent and peripherally preferred melatonin receptor agonist that reduces liver triglycerides and steatosis in diet‐induced obese rats. J Med Chem. 2021;64:1904‐1929.
Zlotos DP, Jockers R, Cecon E, Rivara S, Witt‐Enderby PA. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014;57:3161‐3185.
Elisi GM, Scalvini L, Lodola A, Bedini A, Spadoni G, Rivara S. In silico drug discovery of melatonin receptor ligands with therapeutic potential. Expert Opin Drug Discovery. 2022;17:343‐354.
Morellato L, Lefas‐Le Gall M, Langlois M, et al. Synthesis of new N‐(arylcyclopropyl)acetamides and N‐(arylvinyl)acetamides as conformationally‐restricted ligands for melatonin receptors. Bioorg Med Chem Lett. 2013;23:430‐434.
Koike T, Hoashi Y, Takai T, et al. 1,6‐Dihydro‐2H‐indeno[5,4‐b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT2‐selective agonists. J Med Chem. 2011;54:3436‐3444.
Koike T, Takai T, Hoashi Y, et al. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9‐Dihydrofuro[3,2‐c]pyrazolo[1,5‐a]pyridines as melatonin receptor (MT1/MT2) ligands. J Med Chem. 2011;54:4207‐4218.
Lavedan C, Forsberg M, Gentile AJ. Tasimelteon: a selective and unique receptor binding profile. Neuropharmacology. 2015;91:142‐147.
Davies DJ, Garratt PJ, Tocher DA, et al. Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept[b]indoles. J Med Chem. 1998;41:451‐467.
Spadoni G, Balsamini C, Diamantini G, et al. Conformationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study. J Med Chem. 1997;40:1990‐2002.
Jellimann C, Mathé‐Allainmat M, Andrieux J, et al. Synthesis of phenalene and acenaphthene derivatives as new conformationally restricted ligands for melatonin receptors. J Med Chem. 2000;43:4051‐4062.
Dubocovich ML, Masana MI, Iacob S, Sauri DM. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn‐Schmiedeberg's Arch Pharmacol. 1997;355:365‐375.
Mor M, Spadoni G, Di Giacomo B, et al. Synthesis, pharmacological characterization and QSAR studies on 2‐substituted indole melatonin receptor ligands. Bioorg Med Chem. 2001;9:1045‐1057.
Faust R, Garratt PJ, Jones R, et al. Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H‐Isoindolo[2,1‐a]indoles, 5,6‐Dihydroindolo[2,1‐a]isoquinolines, and 6,7‐Dihydro‐5H‐benzo[c]azepino[2,1‐a]indoles. J Med Chem. 2000;43:1050‐1061.
Spadoni G, Balsamini C, Diamantini G, et al. 2‐N‐acylaminoalkylindoles: design and quantitative structure‐activity relationship studies leading to MT2‐selective melatonin antagonists. J Med Chem. 2001;44:2900‐2912.
Bedini A, Lucarini S, Spadoni G, et al. Toward the definition of stereochemical requirements for MT2‐selective antagonists and partial agonists by studying 4‐phenyl‐2‐propionamidotetralin derivatives. J Med Chem. 2011;54:8362‐8372.
Rivara S, Mor M, Silva C, et al. Three‐dimensional quantitative structure‐activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation. J Med Chem. 2003;46:1429‐1439.
Pala D, Lodola A, Bedini A, Spadoni G, Rivara S. Homology models of melatonin receptors: challenges and recent advances. Int J Mol Sci. 2013;14:8093‐8121.
Spadoni G, Bedini A, Diamantini G, et al. Synthesis, enantiomeric resolution, and structure–activity relationship study of a series of 10,11‐Dihydro‐5H‐Dibenzo[a,d]cycloheptene MT2Receptor antagonists. ChemMedChem. 2007;2:1741‐1749.
Lucini V, Pannacci M, Scaglione F, et al. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity. J Med Chem. 2004;47:4202‐4212.
Wallez V, Durieux‐Poissonnier S, Chavatte P, et al. Synthesis and structure‐affinity‐activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands. J Med Chem. 2002;45:2788‐2800.
Zlotos DP, Attia MI, Julius J, Sethi S, Witt‐Enderby PA. 2‐[(2,3‐Dihydro‐1H‐indol‐1‐yl)methyl]melatonin analogues: a novel class of MT2‐selective melatonin receptor antagonists. J Med Chem. 2009;52:826‐833.
Heckman D, Attia MI, Behnam MAM, et al. 2‐[(1,3‐Dihydro‐2H‐isoindol‐2‐yl)methyl]melatonin – a novel MT2‐selective melatonin receptor antagonist. MedChemComm. 2011;2:991.
Fisher SP, Sugden D. Sleep‐promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat. Neurosci Lett. 2009;457:93‐96.
Poissonnier‐Durieux S, Ettaoussi M, Pérès B, et al. Synthesis of 3‐phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands. Bioorg Med Chem. 2008;16:8339‐8348.
Ettaoussi M, Sabaouni A, Rami M, et al. Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5‐HT2C dual ligands (I). Eur J Med Chem. 2012;49:310‐323.
Bedini A, Spadoni G, Gatti G, et al. Design and synthesis of N‐(3,3‐diphenylpropenyl)alkanamides as a novel class of high‐affinity MT2‐selective melatonin receptor ligands. J Med Chem. 2006;49:7393‐7403.
Rivara S, Lodola A, Mor M, et al. N‐(substituted‐anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem. 2007;50:6618‐6626.
Ochoa‐Sanchez R, Comai S, Lacoste B, et al. Promotion of non‐rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci. 2011;31:18439‐18452.
Ochoa‐Sanchez R, Rainer Q, Comai S, et al. Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: comparison with melatonin and diazepam. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:318‐325.
Rivara S, Vacondio F, Fioni A, et al. N‐(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands. ChemMedChem. 2009;4:1746‐1755.
Lopez‐Canul M, Palazzo E, Dominguez‐Lopez S, et al. Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways. Pain. 2015;156:305‐317.
Hu Y, Zhu J, Chan KH, Wong YH. Development of substituted N‐[3‐(3‐methoxylphenyl)propyl] amides as MT2‐selective melatonin agonists: improving metabolic stability. Bioorg Med Chem. 2013;21:547‐552.
Spadoni G, Bedini A, Lucarini S, et al. Highly potent and selective MT2 melatonin receptor full agonists from conformational analysis of 1‐Benzyl‐2‐acylaminomethyl‐tetrahydroquinolines. J Med Chem. 2015;58:7512‐7525.
Comai S, de Gregorio D, Posa L, Ochoa‐Sanchez R, Bedini A, Gobbi G. Dysfunction of serotonergic activity and emotional responses across the light‐dark cycle in mice lacking melatonin MT2 receptors. J Pineal Res. 2020;69:e12653.
Patel N, Huang XP, Grandner JM, et al. Structure‐based discovery of potent and selective melatonin receptor agonists. eLife. 2020;9:e53779.
Descamps‐François C, Yous S, Chavatte P, et al. Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. J Med Chem. 2003;46:1127‐1129.
Spadoni G, Bedini A, Orlando P, et al. Bivalent ligand approach on N‐{2‐[(3‐methoxyphenyl)methylamino]ethyl}acetamide: synthesis, binding affinity and intrinsic activity for MT1 and MT2 melatonin receptors. Bioorg Med Chem. 2011;19:4910‐4916.
Zlotos DP, Riad NM, Osman MB, Dodda BR, Witt‐Enderby PA. Novel difluoroacetamide analogues of agomelatine and melatonin: probing the melatonin receptors for MT 1 selectivity. MedChemComm. 2015;6:1340‐1344.
Sun L‐Q, Chen J, Takaki K, et al. Design and synthesis of benzoxazole derivatives as novel melatoninergic ligands. Bioorg Med Chem Lett. 2004;14:1197‐1200.
Markl C, Clafshenkel WP, Attia MI, Sethi S, Witt‐Enderby PA, Zlotos DP. N‐Acetyl‐5‐arylalkoxytryptamine analogs: probing the melatonin receptors for MT(1) ‐selectivity. Arch Pharm. 2011;344:666‐674.
Mésangeau C, Pérès B, Descamps‐François C, et al. Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands. Bioorg Med Chem. 2010;18:3426‐3436.
Rivara S, Pala D, Lodola A, et al. MT1‐Selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation ofN‐{[(3‐O‐Substituted)anilino]alkyl}amides. ChemMedChem. 2012;7:1954‐1964.
Di Giacomo B, Bedini A, Spadoni G, et al. Synthesis and biological activity of new melatonin dimeric derivatives. Bioorg Med Chem. 2007;15:4643‐4650.
He F, Chou CJ, Scheiner M, et al. Melatonin‐ and ferulic acid‐based HDAC6 selective inhibitors exhibit pronounced immunomodulatory effects in vitro and neuroprotective effects in a pharmacological Alzheimer's disease mouse model. J Med Chem. 2021;64:3794‐3812.
Rodríguez‐Franco MI, Fernández‐Bachiller MI, Pérez C, Hernández‐Ledesma B, Bartolomé B. Novel tacrine‐melatonin hybrids as dual‐acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J Med Chem. 2006;49:459‐462.
Gerenu G, Liu K, Chojnacki JE, et al. Curcumin/melatonin hybrid 5‐(4‐Hydroxy‐phenyl)‐3‐oxo‐pentanoic acid [2‐(5‐Methoxy‐1H‐indol‐3‐yl)‐ethyl]‐amide ameliorates AD‐like pathology in the APP/PS1 mouse model. ACS Chem Neurosci. 2015;6:1393‐1399.
Michalska P, Buendia I, Duarte P, et al. Melatonin‐sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization. Pharmacol Res. 2020;152:104597.
Hasan M, Marzouk MA, Adhikari S, et al. Pharmacological, mechanistic, and pharmacokinetic assessment of novel melatonin‐tamoxifen drug conjugates as breast cancer drugs. Mol Pharmacol. 2019;96:272‐296.
Witt‐Enderby PA, Davis VL, Lapinsky D. inventors. Anti‐cancer tamoxifen‐melatonin hybrid ligand. U.S. Patent 8, 785:501.
Helmi YY, Papenkordt N, Rennar G, et al. Melatonin‐vorinostat hybrid ligands show higher histone deacetylase and cancer cell growth inhibition than vorinostat. Arch Pharm. 2023;356:e2300149.
Spadoni G, Bedini A, Furiassi L, et al. Identification of bivalent ligands with melatonin receptor agonist and Fatty Acid Amide Hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit. J Med Chem. 2018;61:7902‐7916.
Cammarota M, Ferlenghi F, Vacondio F, et al. Combined targeting of fatty acid amide hydrolase and melatonin receptors promotes neuroprotection and stimulates inflammation resolution in rats. Br J Pharmacol. 2023;180:1316‐1338.
Journé A‐S, Habib SAM, Dodda BR, et al. N1‐linked melatonin dimers as bivalent ligands targeting dimeric melatonin receptors. MedChemComm. 2014;5:792.
Karamitri A, Sadek MS, Journé A‐S, et al. O‐linked melatonin dimers as bivalent ligands targeting dimeric melatonin receptors. Bioorg Chem. 2019;85:349‐356.
Dubocovich ML. Luzindole (N‐0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther. 1988;246:902‐910.
Jin X, von Gall C, Pieschl RL, et al. Targeted disruption of the mouse Mel(1b) melatonin receptor. Mol Cell Biol. 2003;23:1054‐1060.
Sumaya IC, Masana MI, Dubocovich ML. The antidepressant‐like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT2 but not MT1 melatonin receptors. J Pineal Res. 2005;39:170‐177.
Yasuo S, Yoshimura T, Ebihara S, Korf HW. Melatonin transmits photoperiodic signals through the MT1 melatonin receptor. J Neurosci. 2009;29:2885‐2889.
Liu D, Wei N, Man H‐Y, Lu Y, Zhu LQ, Wang JZ. The MT2 receptor stimulates axonogenesis and enhances synaptic transmission by activating Akt signaling. Cell Death Differ. 2015;22:583‐596.
Tchio C, Baba K, Piccione G, Tosini G. Removal of melatonin receptor type 1 signalling induces dyslipidaemia and hormonal changes in mice subjected to environmental circadian disruption. Endocrinol Diabetes Metab. 2021;4:e00171.
Suofu Y, Li W, Jean‐Alphonse FG, et al. Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release. Proc Nat Acad Sci. 2017;114:E7997‐E8006.
Somalo‐Barranco G, Pagano Zottola AC, Abdulrahman AO, et al. Mitochondria‐targeted melatonin photorelease supports the presence of melatonin MT1 receptors in mitochondria inhibiting respiration. Cell Chem Biol. 2023;30:920‐932.e7.
Zhang C, Yang L, Yang X, Gao Q, Qu Y, Wu L. Design, synthesis, and biological evaluation of novel napabucasin‐melatonin hybrids as potent STAT3 inhibitors. Bioorg Chem. 2023;136:106541.